ART26.12 is a novel fatty acid‐binding protein 5 inhibitor, which our group showed could prevent and treat persistent pain in a preclinical model of oxaliplatin‐induced peripheral neuropathy. The gene discussed is FABP5; the disease is peripheral neuropathy.